• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

世界卫生组织 CNS5 2021 年胶质瘤分类:病理学家实用解读及诊断路标,以及恰当的病理临床与神经肿瘤学合作。

WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation.

机构信息

Department of Pathomorphology and Forensic Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.

Department of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.

出版信息

Folia Neuropathol. 2022;60(2):137-152. doi: 10.5114/fn.2022.118183.

DOI:10.5114/fn.2022.118183
PMID:35950467
Abstract

The 5th edition of World Health Organization (WHO) Central Nervous System (CNS) tumours classification has transformed the pathological diagnosis of gliomas from purely histological to the multilayered integrated one with molecular biomarkers necessary for proper classification, risk stratification, and prognostic-predictive clinical purposes. Because of deep and important changes in taxonomy and diagnostic approach to gliomas, this manuscript is a review of WHO CNS classification 5th edition with general testing guidance for pathologists and clinicians working in neuro-oncology.

摘要

世界卫生组织(WHO)第五版中枢神经系统(CNS)肿瘤分类将胶质瘤的病理诊断从单纯的组织学转变为多层次的综合诊断,需要分子生物标志物来进行正确的分类、风险分层和预后预测的临床目的。由于胶质瘤的分类和诊断方法发生了深刻而重要的变化,因此本文档是对 WHO CNS 分类第五版的综述,为神经肿瘤学领域的病理学家和临床医生提供了一般检测指导。

相似文献

1
WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation.世界卫生组织 CNS5 2021 年胶质瘤分类:病理学家实用解读及诊断路标,以及恰当的病理临床与神经肿瘤学合作。
Folia Neuropathol. 2022;60(2):137-152. doi: 10.5114/fn.2022.118183.
2
What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas.CNS5 有何变化?关于一般变化和成人弥漫性神经胶质瘤的简要综述。
Ann Afr Med. 2024 Jul 1;23(3):255-261. doi: 10.4103/aam.aam_63_23. Epub 2024 Jul 20.
3
Updates on the WHO diagnosis of IDH-mutant glioma.关于 IDH 突变型胶质瘤的世卫组织诊断更新。
J Neurooncol. 2023 May;162(3):461-469. doi: 10.1007/s11060-023-04250-5. Epub 2023 Jan 30.
4
[The 2021 WHO Classification of Tumors, 5th edition, Central Nervous System Tumors: A Short Review].[《2021年世界卫生组织中枢神经系统肿瘤分类》第5版:简要回顾]
Brain Nerve. 2022 Jun;74(6):803-809. doi: 10.11477/mf.1416202124.
5
Classification and Grading of Central Nervous System Tumors According to the World Health Organization 5th Edition.根据世界卫生组织第五版对中枢神经系统肿瘤的分类和分级。
Semin Neurol. 2023 Dec;43(6):833-844. doi: 10.1055/s-0043-1776793. Epub 2023 Nov 10.
6
Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors.2021 年世界卫生组织中枢神经系统肿瘤分类发布前弥漫性神经胶质瘤的临床实验室检测实践。
Arch Pathol Lab Med. 2022 May 1;147(5):518-524. doi: 10.5858/arpa.2021-0431-CP.
7
Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.2021 年世界卫生组织中枢神经系统肿瘤分类的重大变化。
Radiographics. 2022 Sep-Oct;42(5):1474-1493. doi: 10.1148/rg.210236. Epub 2022 Jul 8.
8
Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.分子神经肿瘤学的应用——弥漫性胶质瘤综合诊断及新兴分子实体综述
Diagn Pathol. 2019 Apr 9;14(1):29. doi: 10.1186/s13000-019-0802-8.
9
Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System.弥漫性胶质瘤:2016 年世界卫生组织中枢神经系统肿瘤分类之后的进展。
Int J Clin Oncol. 2020 Jun;25(6):997-1003. doi: 10.1007/s10147-020-01695-w. Epub 2020 May 28.
10
[The 2021 WHO classification of tumours of the central nervous system].[2021年世界卫生组织中枢神经系统肿瘤分类]
Ann Pathol. 2022 Oct;42(5):367-382. doi: 10.1016/j.annpat.2021.11.005. Epub 2021 Dec 2.

引用本文的文献

1
The Potential Anti-Cancer Effects of Polish Ethanolic Extract of Propolis and Quercetin on Glioma Cells Under Hypoxic Conditions.波兰蜂胶乙醇提取物和槲皮素在缺氧条件下对胶质瘤细胞的潜在抗癌作用
Molecules. 2025 Jul 17;30(14):3008. doi: 10.3390/molecules30143008.
2
Dietary Polyphenols: Luteolin, Quercetin, and Apigenin as Potential Therapeutic Agents in the Treatment of Gliomas.膳食多酚:木犀草素、槲皮素和芹菜素作为治疗神经胶质瘤的潜在治疗剂
Nutrients. 2025 Jul 1;17(13):2202. doi: 10.3390/nu17132202.
3
Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.
2009年至2021年德国世界卫生组织2级和3级胶质瘤的流行病学
J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05068-z.
4
Pediatric-type diffuse high-grade glioma with systemic metastasis: A case report.伴有全身转移的儿童型弥漫性高级别胶质瘤:一例报告
Neurooncol Adv. 2025 Apr 3;7(1):vdaf069. doi: 10.1093/noajnl/vdaf069. eCollection 2025 Jan-Dec.
5
Identification and validation of LY6H and GRM3 as candidate biomarkers for Glioma-related epilepsy.鉴定和验证LY6H和GRM3作为胶质瘤相关癫痫的候选生物标志物。
Sci Rep. 2025 Apr 14;15(1):12833. doi: 10.1038/s41598-025-97333-4.
6
Potential of Curcumin and Its Analogs in Glioblastoma Therapy.姜黄素及其类似物在胶质母细胞瘤治疗中的潜力。
Antioxidants (Basel). 2025 Mar 18;14(3):351. doi: 10.3390/antiox14030351.
7
Development and validation of disulfidptosis-related genes signature for patients with glioma.胶质瘤患者二硫化物相关基因特征的开发与验证
Discov Oncol. 2024 Dec 18;15(1):758. doi: 10.1007/s12672-024-01664-z.
8
Recent updates in pediatric diffuse glioma classification: insights and conclusions from the WHO 5 edition.儿童弥漫性神经胶质瘤分类的最新进展:WHO 第 5 版的见解和结论。
J Med Life. 2024 Jul;17(7):665-670. doi: 10.25122/jml-2023-0515.
9
The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas.全身治疗在1-4级胶质瘤治疗中的作用
Cureus. 2024 Sep 30;16(9):e70532. doi: 10.7759/cureus.70532. eCollection 2024 Sep.
10
Signature Genes Selection and Functional Analysis of Astrocytoma Phenotypes: A Comparative Study.星形细胞瘤表型的特征基因选择与功能分析:一项比较研究
Cancers (Basel). 2024 Sep 25;16(19):3263. doi: 10.3390/cancers16193263.